Anzeige
Meldung des Tages: Diese Entwicklung im KI-Sektor könnte unterschätzt werden — und sie betrifft die Energieversorgung

Idorsia News

Aktie
WKN:  A2DTEB ISIN:  CH0363463438 US-Symbol:  IDRSF Branche:  Biotechnologie Land:  Schweiz
3,515 CHF
-0,095 CHF
-2,63%
3,8141 € 02.04.26
Depot/Watchlist
Marktkapitalisierung *
858,56 Mio. €
Streubesitz
55,25%
KGV
-0,58
Index-Zuordnung
-

Idorsia News

09.10.25 - GlobeNewswire
Idorsia launches an offering of registered shares – to fund the company to overall profitability
Ad hoc announcement pursuant to Art. 53 LR
22.09.25 - GlobeNewswire
Global expansion of Idorsia’s QUVIVIQ continues as Simcere launches in China
Allschwil, Switzerland – September 22, 2025 Idorsia Ltd. (SIX: IDIA) announces that Simcere Pharmaceuticals Group Ltd (2096.HK, “Simcere”) has launched QUVIVIQ ® (daridorexant) ...
19.09.25 - GlobeNewswire
Idorsia’s JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension
Idorsia receives approval from Swissmedic for JERAYGO ™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension. ...
10.09.25 - GlobeNewswire
Idorsia shares new analyses of daridorexant for patients with insomnia at World Sleep 2025
Allschwil, Switzerland – September 10, 2025 Idorsia Ltd (SIX: IDIA) shares new analyses of daridorexant for patients with insomnia and further characterizes insomnia disorder at ...
08.09.25 - GlobeNewswire
Idorsia highlights very low real-world abuse potential of DORA class for insomnia treatment at WSC 2025
Analysis of the FAERS database shows that the real-​world abuse potential of the DORA class is very low and markedly less than those seen for other scheduled and non-​scheduled ...
05.09.25 - GlobeNewswire
Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN – a US initiative to transform care for patients with difficult-to-control hypertension
Multi-​phase program to standardize treatment, generate real-​world evidence and explore AI-​powered tools to improve outcomes for hypertension patients Allschwil, Switzerland & ...
03.09.25 - GlobeNewswire
Invitation to Idorsia’s aprocitentan (TRYVIO/JERAYGO) investor Q&A webcast and conference call
Idorsia will host a live investor Q&A webcast and conference call following the publication of the  OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only ...
01.09.25 - GlobeNewswire
Idorsia furthers the science of sleep and insomnia at World Sleep 2025
Allschwil, Switzerland – September 1, 2025 Idorsia Ltd (SIX: IDIA) continues its commitment to furthering the science of sleep and insomnia with a symposium and eight poster ...
28.08.25 - GlobeNewswire
Idorsia’s TRYVIO – First FDA-approved therapy to target the endothelin pathway for systemic hypertension
Allschwil, Switzerland – August 28, 2025 Idorsia Ltd (SIX: IDIA) releases an OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertension therapy ...
27.08.25 - GlobeNewswire
Idorsia successfully completes convertible bonds restructuring
Ad hoc announcement pursuant to Art. 53 LR
19.08.25 - GlobeNewswire
TRYVIO™ (aprocitentan) now included in ACC/AHA Clinical Practice Guidelines for the treatment of hypertension
The updated recommendations now include TRYVIO™ (aprocitentan) – the first and only hypertension treatment targeting the endothelin pathway. Endothelin is upregulated in ...
19.08.25 - GlobeNewswire
Idorsia publishes end results of repurchase offer for its 2025 and 2028 convertible bonds
Ad hoc announcement pursuant to Art. 53 LR
12.08.25 - GlobeNewswire
TRYVIO nominated for the 2025 Prix Galien USA “Best Pharmaceutical Product”
Allschwil, Switzerland – August 12, 2025 Idorsia Ltd (SIX: IDIA) announced today that The Galien Foundation, the premier global institution dedicated to honoring innovators in life ...
11.08.25 - GlobeNewswire
Idorsia publishes interim results of repurchase offer for its 2025 and 2028 convertible bonds
Ad hoc announcement pursuant to Art. 53 LR
30.07.25 - GlobeNewswire
Strong sales acceleration of QUVIVIQ drives Idorsia toward profitability – H1 2025 results
Ad hoc announcement pursuant to Art. 53 LR
23.07.25 - GlobeNewswire
Invitation to Idorsia's HY 2025 Financial Reporting webcast and conference call with our new CEO Srishti Gupta
Idorsia will publish its Half Year 2025 Financial Reporting on Wednesday July 30, at 07:00 CEST.
30.06.25 - GlobeNewswire
A factory in a lab: Idorsia's breakthrough synthetic glycan vaccine platform validated for the first time in humans
Ad hoc announcement pursuant to Art. 53 LR
25.06.25 - GlobeNewswire
Bondholders approve amended terms of the 2025 and 2028 convertible bonds
Ad hoc announcement pursuant to Art. 53 LR
25.06.25 - GlobeNewswire
Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds
Ad hoc announcement pursuant to Art. 53 LR
23.06.25 - GlobeNewswire
Idorsia’s QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia and Simcere update their licensing agreement
Ad hoc announcement pursuant to Art. 53 LR

Newssuche

Videos

newspaper
03.04.26
RW QUANTUM Strategie Einführung
Am Sonntag, den 12.4.26 wird erstmals die RW QUANTUM Strategie geschult. Der Ansatz handelt die ... Mehr »